scar hyperplasia
Conditions
Interventions
Experimental group:Injection of botox
Sponsors
Shenzhen Hospital of Peking University
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1) Participants who voluntarily participate in the clinical study and sign a written informed consent; 2) Male and female patients aged 18 to 45; 3) Patients who have congenital epicanthus that need to be corrected; 4) Patients who understand and comply with the research requirements and can finish the whole progress.
Exclusion criteria
Exclusion criteria: 1) Women who are pregnant or breastfeeding; 2) Women of reproductive age do not agree to take medically approved contraceptive measures such as oral contraceptives, condoms, intrauterine devices (IUDS) during the trial; 3) Patients with locally active skin diseases, such as psoriasis and herpes simplex; 4) Patients with scar or skin disease in the treatment area that may affect the judgment of treatment effectiveness, or with active and/or unhealed wounds; 5) Epicanthus is acquired epicanthus or combined with ptosis;Secondary epicanthus correction was performed; 6)Patients with hypertrophic scar or scar constitution; 7) Patients with a history of serious diseases of important organs or autoimmune diseases; 8) Patients with known allergy to botox or symptoms of muscle weakness; 9) Patients who have participated in other clinical trials within 30 days prior to the screening period; 10) Patients considered unsuitable for this study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scar score using modified SBSES scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| OSAS;PSAS;width of the scar;VAS; | — |
Countries
China
Contacts
Public ContactDandan Liu
Shenzhen Hospital of Peking University
Outcome results
None listed